Biotech Values

[DewDiligence]

Telaprevir vs Boceprevir in First- and Second-Line Settings

 
                                       SVR in best     SVR in      SVR   iHub 
 Trial design      Setting   Acronym  treatment arm  control arm  Delta  reference  
 SoC ± Telaprevir  1st-line  ADVANCE   *75% (n=362)  44% (n=369)   31%   #msg-50595752 
 Soc ± Boceprevir  1st-line  SPRINT-2  †66% (n=366)  38% (n=366)   28%   #msg-52949888 
  
 SoC ± Telaprevir  2nd-line  PROVE-3   ‡53% (n=151)  14% (n=151)   39%   #msg-48759554 
 Soc ± Boceprevir  2nd-line  RESPOND-2 †66% (n=134)  21% (n=134)   45%   #msg-52949888 

* ‘12+12’ arm. (SVR in ‘8+16’ arm was 73%.)

† 48w arm with 4w lead-in on SoC alone. (SVR in ‘response-guided’ arm
was 63% in SPRINT-2 and 59% in RESPOND-2.) No breakdown of patients
by response to first-line treatment is available for RESPOND-2 at this time.

‡ ’24+24’ arm. (SVR in ‘12+12’ arm was 51%.) 57% of patients were prior
non-responders, 7% were prior breakthroughs, and 36% were prior relapsers.